Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma

More than half of patients with malignant mesothelioma show alterations in the BAP1 tumor-suppressor gene. Being a member of the Polycomb repressive deubiquitinating (PR-DUB) complex, BAP1 loss results in an altered epigenome, which may create new vulnerabilities that remain largely unknown. Here, w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell reports. Medicine Jg. 4; H. 2; S. 100915
Hauptverfasser:	Pandey, Gaurav Kumar, Landman, Nick, Neikes, Hannah K., Hulsman, Danielle, Lieftink, Cor, Beijersbergen, Roderick, Kolluri, Krishna Kalyan, Janes, Sam M., Vermeulen, Michiel, Badhai, Jitendra, van Lohuizen, Maarten
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 21.02.2023 Elsevier
Schlagworte:	Advanced Basic Science Animals BAP1 Cholesterol combination therapy EZH2 Humans Lung Neoplasms - genetics mesothelioma Mesothelioma - genetics Mesothelioma - pathology Mesothelioma, Malignant mevalonate Mevalonic Acid Mice Polycomb preclinical models targeted therapy Tumor Suppressor Proteins - genetics Ubiquitin Thiolesterase - genetics Ubiquitin Thiolesterase - metabolism uveal melanoma targeted therapy preclinical models uveal melanoma Polycomb combination therapy mesothelioma mevalonate BAP1 EZH2
ISSN:	2666-3791, 2666-3791
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!